Vectorious: Taking technology to heart. Literally.
HILLEL'S TECH CORNER
is expected to launch a clinical study in the US in 2022.
The Vectorious team, which is now more than 30 members strong, has successfully implanted in-heart micro computers in multiple countries across Europe and Israel. Their clinical study demonstrated huge potential in helping millions of people living with heart failure take control and manage their disease, keeping them stable, out of hospitals, and living longer, fuller lives.
Goldshtein believes that heart failure management will go through the same revolution diabetes management went through: that in the not very far future, every patient with chronic heart disease will be remotely monitored by in-body microsensors that will give real time, accurate indication about how the heart is functioning. No more guessing games and estimations, but accurate data that will enable optimal treatment and will help caregivers make informed decisions to halt the progression of heart failure.
Goldshtein also expects the V-LAP to be an enabler of combined diagnostic and therapeutic medical devices, or in other words, to make devices, like pacemakers and shunts smarter, by enabling them to manage heart diseases remotely.
It is worth noting that as the world realizes the importance of remote medicine and healthcare, Vectorious’ offering becomes significantly more important.
Here’s to wishing the Vectorious team success in achieving the growth they need to make their technology accessible to all. I’d love to see where this company stands five years from now in terms of impact. We can only hope that they can help significantly decrease the number of people suffering greatly from heart failure.